pipette
ENEnglish

Neural autoantibodies in the cerebrospinal fluid of individuals with schizophrenia spectrum disorders

P. R. Pandit, S. L. Listwak, T. T. Ngo, Madeleine Salem, T. J. Esparza, Pavel P. Khil, R. Dandekar, B. D. Alvarenga, GenaLynne C. Mooneyham, Kelly L. Hamilton, Joseph L. DeRisi, Avindra Nath, R. Gomez, Bruce Cree, Stephen L. Hauser, K. A. Fiore, Todd Lencz, J. A. Gallego, Michael Wilson, Samuel J. Pleasure, Christopher M. Bartley

Revista con revisión por pares

En palabras de los autores

Abstract Schizophrenia spectrum disorders have substantial genetic liability, but their stable incidence and clinical heterogeneity leave open contributions from non-genetic mechanisms. Though autoimmune encephalitis demonstrates that anti-neural antibodies can cause psychosis, encephalitis antibodies are uncommon in schizophrenia. Here we show that multi-platform autoantigen profiling of cerebrospinal fluid and plasma detects rare, anti-neural autoantibodies in schizophrenia spectrum disorders. By antibody profiling the cerebrospinal fluid of 32 schizophrenia spectrum participants and 32 neuropsychiatrically unaffected controls by brain tissue immunostaining, immunoprecipitation–mass spectrometry, phage display immunoprecipitation sequencing, and plasma by complementary protein microarrays, we identify three autoantibodies, including to alpha-crystallin B. The anti-alpha-crystallin B antibody preferentially recognizes phosphorylated serine-45 and is absent from the cerebrospinal fluid of individuals with untreated multiple sclerosis, a disease with frequent antibodies to unphosphorylated alpha-crystallin B. These findings do not define autoimmune psychosis as a new disease but support broader autoantibody searches in psychotic disorders.

Resultado principalLimitación que admiten los autores

Apareció: jueves, 5 de noviembre. Nature Communications. Revista con revisión por pares.

DOI: 10.1038/s41467-026-78783-4